GL · Q2 2025 Earnings
BullishGlobe Life
Reported July 23, 2025
30-second summary
Globe Life delivered $3.27 net operating EPS on $1.48B revenue (+3% YoY). The FY2025 EPS guidance range of $14.25–$14.65 was reaffirmed in the press release, but management commentary indicates the midpoint is now higher within the range on favorable mortality, Q3 assumption updates, and slightly better health margins — and they're telegraphing a $110–160M Q3 remeasurement gain. The bigger story is structural: a Bermuda reinsurance entity targeted for year-end could route up to $200M/year of incremental cash to the parent over time, materially changing the capital-return arithmetic. DTC life net sales declined for 16 consecutive quarters before turning positive (+2% YoY, +24% QoQ) this quarter; premium remains -1% YoY but underwriting margin grew 8% to $69M.
Headline numbers
EPS
Q2 FY2025
$3.27
Revenue
Q2 FY2025
$1.48B
+3.0% YoY
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $1.48B | +3.0% |
| EPS | $3.27 | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment performance
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| Life Insurance Premium | $0.84B | +3.0% |
| Health Insurance Premium | $0.38B | +8.0% |
| American Income Division - Life Premium | $0.45B | +5.0% |
| American Income Division - Life Underwriting Margin | $0.2B | +6.0% |
| Direct to Consumer Division - Life Premium | $0.25B | -1.0% |
| Direct to Consumer Division - Life Underwriting Margin | $0.07B | +8.0% |
| Family Heritage Division - Health Premium | $0.12B | +9.0% |
| Family Heritage Division - Health Underwriting Margin | $0.04B | +12.0% |
Capital & returns
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| ROE (Net Income) | 18.8% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Net Operating Income per Share | $3.27 |
| Insurance Underwriting Margin - Life | $340.1M |
| Insurance Underwriting Margin - Health | $98.1M |
| Life Net Sales Growth | +1% |
| Health Net Sales Growth | +19% |
| Excess Investment Income per Share | $0.42 |
| Average Producing Agent Count - Family Heritage | +10% YoY |
Management tone
Management's posture this quarter reads as proactively forward-leaning rather than reactively reporting. Five distinct shifts stand out:
Direct-to-Consumer from drag to turnaround. After 16 consecutive quarters of net sales declines, management labeled Q2 a "turnaround" and explicitly opened the door to reinstating marketing spend that had been pulled. "I am very pleased to see these results as this is a turnaround of a declining trend in recent years…The resulting improvement in return on marketing investment could allow us to reinstate some of the marketing campaigns that were discontinued in the past due to high marketing costs." The signal: management is now willing to spend into this channel rather than ration it.
Bermuda captive from concept to executable lever. The reinsurance entity moved from exploratory framing to a concrete year-end execution target with a quantified upside: "we anticipate establishing a Bermuda Reinsurance entity and executing the first reinsurance transaction by the end of the year…we do see the potential for additional distributable earnings from our subsidiaries to the parent trending over time towards $200 million annually." The $200M figure is ~15% of GAAP operating income — a structurally different capital-return story if delivered.
Life assumption updates from maintenance to catalyst. What is normally a routine Q3 actuarial exercise is now being telegraphed as a $110–160M remeasurement gain. "Due to the continued favorable mortality we are experiencing, we are increasing our estimate on the margin impact for the third quarter life assumption updates." This is the difference between a quarterly housekeeping item and a near-term earnings beat already pre-announced.
2025 guidance midpoint moves up within a reaffirmed range. Management explicitly acknowledged the FY midpoint moved higher on multiple positive revisions — favorable mortality, Q3 assumption updates, and slightly better health margins — even as the headline range was reaffirmed. Three separate drivers in one revision is unusual and points to broad-based execution rather than a single tailwind.
Investment income from headwind to bridge. Rather than dwelling on the -10 to -15% excess investment income decline, management pivoted to sequential growth in H2 and "more normalized growth in 2026." This is teeing up a clean comp.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Jack Nathan · BMO Capital Markets
How should higher earnings guidance translate to statutory earnings and cash flows next year? Is the benefit from experience issues immediate or does it lag? How much of the $200M Bermuda benefit is contingent on moving a quarter of life reserves, and could that target be revised?
Favorable mortality experience translates directly to statutory income and will continue throughout the year. Assumption changes are GAAP-only and don't impact statutory income. Expected Q4 life underwriting margins around 41%. On Bermuda, timing is premature; details will be provided after regulatory discussions and business plan finalization in Q3. The 25% reserve target is preliminary and could change as plans are developed.
Andrew Kligerman · TD Securities
Why lower life insurance sales guidance given strong 6% Q1-Q2 agent count growth? Should 6% agent growth be used as a ballpark for 2026? What about potential pressure on Medicare Supplement sales if Medicare Advantage stabilizes?
Sales guidance revised down to mid-single-digit growth due to timing; new agents take time to become productive while training others. Agent count growth is a leading indicator for 2026 sales. Medicare Supplement will continue to see ebbs and flows based on Medicare Advantage disruption, but fundamentals remain strong. In-force block and premium growth from rate filings support earnings outlook.
Jimmy Buller · JP Morgan
Of the 70-cent guidance increase, how much is one-time remeasurement vs. ongoing earnings assumptions? Is direct sales channel bottoming after 16 quarters of decline? What's the math on achieving ~60% free cash flow conversion post-Bermuda?
Mortality expected to run favorably throughout year (~41% Q4 margins) independent of assumption changes. Also benefiting from favorable health segment trends and admin expense reduction (7.3% guidance). Direct sales showing signs of recovery due to underwriting improvements and lead conversion technology; expect continued improvement. Post-Bermuda cash flow conversion math of 60% is reasonable and dependent on timing of earnings emergence from Bermuda versus U.S. subs.
Ryan Kruger · KBW
The $200M Bermuda benefit represents 15% of GAAP operating income. What's the expected free cash flow conversion post-Bermuda, and when will benefits start emerging?
Math of ~60% conversion is reasonable and aligns with management's view. Benefits expected to emerge in 2027 and beyond. Details will be finalized after business plan completion and regulatory/rating agency discussions. Additional flexibility on capital management and dividend timing are key benefits.
Wilma Burgers · Raymond James
How will mortality remeasurement gains flow through future years as reserves accumulate? Are current health business margins sustainable?
Current life mortality assumption expected to be in line with pre-pandemic levels; recent experience running below that level, yielding remeasurement gains. Expect continued gains if favorable mortality persists, but expect reversion to long-term averages over time. Margins expected around 40.5-41% at long-term assumption levels, with potential slight degradation due to LDTI amortization transition. Health business margins are stable and sustainable at current levels.
What to watch into next quarter
Q3 remeasurement gain lands in the $110–160M range. Management has pre-announced this; a print at or above the high end signals continued mortality favorability and reinforces the structural margin step-up. A figure below $110M would be the first crack in the bullish mortality narrative.
Bermuda entity established by year-end with first reinsurance transaction executed. This is the binary catalyst. Slippage into 2026 would push the $200M cash-flow uplift further out and weaken the capital-return thesis.
Direct-to-Consumer life premium turns positive YoY. Net sales already inflected (+2% YoY, +24% QoQ); premium -1% suggests the top line is close behind. A positive premium print in Q3 would confirm the channel decline is over and validate reinstating marketing spend.
Agent count growth sustains above mid-single-digits. Management framed agent count as the 2026 sales leading indicator. Continued ~6% sequential growth across the exclusive agencies (Q2 vs Q1), or sustained 10% YoY at Family Heritage, feeds the 2026 setup; deceleration undermines it.
Health underwriting margin holds in the 25–27% FY guide band. Management noted that health claim cost trends are running higher than reflected in recent rate filings — a deterioration in Q3 would signal pricing/claims pressure starting to bite.
Share repurchases pace toward $600–650M for the year. With stock weakness cited as motivation for accelerating buybacks, watch whether Q3 dollar volume picks up if the price stays soft (management guided ~$100–125M in Q3).
Sources
- Globe Life Q2 FY2025 earnings release — https://www.sec.gov/Archives/edgar/data/320335/000032033525000040/q2fy2025earningsrelease.htm
- Globe Life Q2 FY2025 earnings call transcript and prepared remarks (management guidance commentary and analyst Q&A)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.